84 results found.

Chronic Hepatitis C, Hepatitis C Virus, or Compensated Cirrhosis Clinical Trial using ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

AbbVie - Recruiting 18 years to 70 years.
- A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

Hepatitis C Clinical Trial

Hologic, Inc. - Recruiting 18 years or older.
- Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay.

Hepatitis C, Chronic, or Infection Clinical Trial using TMC435; Pegylated interferon alfa-2a (PegIFNà-2a); Ribavirin (RBV)

Janssen-Cilag International NV - Recruiting 18 years to 70 years.
- A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Na‹ve Subjects With Chronic Genotype 1 or Genotype 4 HCV Infection.
TMC435; Pegylated interferon alfa-2a (PegIFNà-2a); Ribavirin (RBV)

Hepatitis B, Chronic, or Tumor Clinical Trial using TDF

Chang Gung Memorial Hospital - Recruiting 18 years to 70 years.
- Phase IV; Different Extend Treatment Duration (6 Months vs 12 Months After Chemotherapy) to Prevent HBV Relapse With Tenofovir for Prophylaxis in Patients With Malignant Tumor Combined With HBV Carrier Receiving Chemotherapy.
TDF

Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirr Clinical Trial using IDN-6556

Conatus Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure.
IDN-6556

Chronic Hepatitis B Clinical Trial using Telbivudine 600mg; Tenofovir disoproxil fumarate 300mg

Novartis - Recruiting 18 years or older.
- OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept.
Telbivudine 600mg; Tenofovir disoproxil fumarate 300mg

Hepatocellular Carcinoma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects With or Without Chronic Viral Hepatitis.
Nivolumab

Hepatitis B, Chronic Clinical Trial using PEG-IntronT; PEGASYST

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-IntronT Versus PEGASYST in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450).
PEG-IntronT; PEGASYST

Chronic Hepatitis B Clinical Trial using tenofovir; entecavir

Korea University - Recruiting 19 years or older.
- .
tenofovir; entecavir

Hepatitis C Clinical Trial using TT-034

Tacere Therapeutics, Inc. - Recruiting 18 years to 65 years.
- A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection.
TT-034

Hepatitis B Chronic Infection, or Pregnancy Clinical Trial using tenofovir disoproxil fumarate; placebo

Institut de Recherche pour le Developpement - Recruiting 18 years or older.
- Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization..
tenofovir disoproxil fumarate; placebo

Hepatitis B, Chronic Clinical Trial using peginterferon alfa-2a [Pegasys]

Hoffmann-La Roche - Recruiting 3 years to 17 years.
- A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children With HBeAg Positive Chronic Hepatitis B.
peginterferon alfa-2a [Pegasys]

De Novo Autoimmune Hepatitis Clinical Trial using Pediatric transplant subject with d-AIH; Pediatric transplant subject with acute rejection; Pediatric transplant subject with chronic rejection; Adult non-transplant patients with auto-immune hepatitis; Adult non-transplant subjects with chronic hepatitis C virus; Pediatric control subjects

Yale University - Recruiting 3 Months to 50 years.
- De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation.
Pediatric transplant subject with d-AIH; Pediatric transplant subject with acute rejection; Pediatric transplant subject with chronic rejection; Adult non-transplant patients with auto-immune hepatitis; Adult non-transplant subjects with chronic hepatitis C virus; Pediatric control subjects

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Prospective Multicenter Observational Trial to Evaluate Correlation Between Liver Biopsy and Transient Elastography in Liver Fibrosis Assessment and Correlation Between Viral Kinetics and Transient Elastography Evolution During Hepatitis C Treatment in a Population of Chronic HCV Infected Patients.

Chronic Hepatitis C Clinical Trial using LDV/SOF FDC; SOF; RBV; PEG; GS-9669; GS-5816

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection.
LDV/SOF FDC; SOF; RBV; PEG; GS-9669; GS-5816

Hepatitis C Clinical Trial using MK-5172; MK-8742; Placebo; Ribavirin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ñ Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection.
MK-5172; MK-8742; Placebo; Ribavirin

Hepatitis, Chronic Clinical Trial

Janssen Pharmaceutica N.V., Belgium - Recruiting 18 years or older.
- Observational Multicenter Study in Ex-People Who INject Drugs (Ex-PWIDs) to Evaluate Efficacy, Safety, and Adherence to TElaprevir in Combination With Pegylated Interferon Alfa and Ribavirin in Genotype 1 ChRonic HepATitis C PatiEnts.

Hepatitis C, Chronic Clinical Trial using PEG-IFN alfa-2b; ribavirin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Randomized Open Label Study to Assess the Efficacy and Safety of Short Course Therapy (24 Weeks) With Peginterferon Alpha-2b and Ribavirin for Chronic Hepatitis C (Genotype 4) Patients Who Achieve a Rapid Virological Response (HCV -RNA Undetectable at Week 4 of Treatment).
PEG-IFN alfa-2b; ribavirin

Hepatitis C, Chronic Clinical Trial using Faldaprevir; BI 207127; BI 207127 high dose; Ribavirin placebo; BI 207127 high dose placebo; Ribavirin; Faldaprevir placebo; BI 207127 low dose; BI 207127 low dose placebo

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A Phase III Randomised, Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection.
Faldaprevir; BI 207127; BI 207127 high dose; Ribavirin placebo; BI 207127 high dose placebo; Ribavirin; Faldaprevir placebo; BI 207127 low dose; BI 207127 low dose placebo

Chronic Hepatitis B e Antigen Positive, or Chronic Hepatitis B e Clinical Trial using Tenofovir/ & amp; Emtricitabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B.
Tenofovir/ & amp; Emtricitabine

Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area.

Hepatitis C Chronic Clinical Trial

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- An Observational Post-Authorization Safety Study (PASS) of VictrelisT (Boceprevir) Among Chronic Hepatitis C Patients.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Non-comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Real Clinical Practice.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients.

Hepatitis C Clinical Trial using Peginterferon lambda

Nanogen Pharmaceutical Biotechnology Co., Ltd - Recruiting 18 years to 65 years.
- The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients.
Peginterferon lambda

Purpura, Thrombocytopenic, Idiopathic and Hepatitis C Clinical Trial using eltrombopag; placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind and Open-label Phase III Study To Compare The Efficacy And Safety Of Eltrombopag With Placebo In Chinese Chronic ITP Patients.
eltrombopag; placebo

Hepatitis C, Liver Disease Clinical Trial using DEB025 200mg; DEB025 300mg; DEB025 400mg

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment na‹ve Patients.
DEB025 200mg; DEB025 300mg; DEB025 400mg

Hepatitis C Clinical Trial using DCV/ASV/BMS-791325

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C.
DCV/ASV/BMS-791325

Hepatitis B, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 4, Blood Sample Collection Study For Exploratory Evaluation of the Association of Single Nucleotide Polymorphisms With Treatment Responses From Subjects With HBE-Antigen Positive or Negative Chronic Hepatitis B, Who Received Therapy for Hepatitis B With Peginterferon Alfa-2A 40KD (PEG-IFN) +/- Nucleos(t)Ide Analogue.

Chronic Hepatitis C Infection Clinical Trial using JNJ-47910382 30 mg; JNJ-47910382 90 mg; JNJ-47910382 200 mg; Placebo

Janssen R&D Ireland - Recruiting 18 years to 70 years.
- A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Asian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens.
JNJ-47910382 30 mg; JNJ-47910382 90 mg; JNJ-47910382 200 mg; Placebo

Hepatitis C, Chronic Clinical Trial using Stop trial intervention for boceprevir, PEG-IFN and RBV

Kaohsiung Medical University Chung-Ho Memorial Hospital - Recruiting 20 years to 80 years.
- Boceprevir-based Triple Therapy to Rescue HCV Genotype 1/HBV Dually Infected Patients Refractory to Peginterferon Plus Ribavirin Combination Therapy.
Stop trial intervention for boceprevir, PEG-IFN and RBV

Hepatitis C, Chronic, or Human Immunodeficiency Virus Clinical Trial using DAA against HCV

Valme University Hospital - Recruiting 18 years or older.
- Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort..
DAA against HCV

Hepatitis C Clinical Trial using MK-5172; MK-8742; Ribavirin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection.
MK-5172; MK-8742; Ribavirin

Hepatitis C Virus Clinical Trial using Pegylated-Interferon-lambda; Ribavirin; Daclatasvir

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Na‹ve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin.
Pegylated-Interferon-lambda; Ribavirin; Daclatasvir

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Prospective, Observational, Multicenter Non-interventional Trial Examining Efficacy of Combination Therapy With PEGASYSr Plus COPEGUSr in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing an Opioid Maintenance-Therapy With Special Focus on Patient Compliance and Quality of Life.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Prospective Observational Study on Predictors of On-treatment Response and Sustained Virological Response in a Cohort of HCV-infected Patients Treated With Pegylated Interferons in Georgia.

Hepatitis B, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL COHORT STUDY IN CHINESE SUBJECTS WITH HBeAg NEGATIVE CHRONIC HEPATITIS B (CHB) RECEIVING THERAPY WITH PEGINTERFERON ALFA.

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers.

Hepatitis B, Chronic Clinical Trial using peginterferon alfa-2a [Pegasys]; nucleos(t)ide analogues

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks PEG-Interferon Alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype D Patients on Treatment With Nucleos(t)Ide Analogues (NAs), Showing Stable HBV DNA Suppression.
peginterferon alfa-2a [Pegasys]; nucleos(t)ide analogues

Hepatitis C, Chronic Clinical Trial using peginterferon alfa-2a; ribavirin; boceprevir

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects.
peginterferon alfa-2a; ribavirin; boceprevir

Hepatitis C Clinical Trial using ABT-450/ritonavir; ABT-333; ABT-267

AbbVie - Recruiting 18 years to 80 years.
- A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection.
ABT-450/ritonavir; ABT-333; ABT-267

CHB Patients Without Significant Alcohol Consumption or Other Kno Clinical Trial

Seoul National University Boramae Hospital - Recruiting 20 years to 80 years.
- Association Between Insulin Resistance and Hepatic Fibrosis in Combined Chronic Hepatitis B and Non-alcoholic Fatty Liver Disease.

Hepatitis C, Chronic Clinical Trial using VGX-6150

VGX International, Inc. - Recruiting 19 years to 65 years.
- Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection.
VGX-6150

Cirrhosis, Chronic Hepatitis C, Hepatitis C, or Hepatitis C, Chro Clinical Trial using Asunaprevir and Daclatsvir; Asunaprevir, daclatsvir, peginterferon, ribavirin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Unraveling the Mechanisms of Non-Response in Patients With and Without Cirrhosis Due to Chronic Hepatitis C.
Asunaprevir and Daclatsvir; Asunaprevir, daclatsvir, peginterferon, ribavirin

Chronic Hepatitis B e Antigen Positive, or Chronic Hepatitis B e Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study).

Hepatitis C, Chronic Clinical Trial using Fixed Dose GS-7977/GS-5885; FDC with GS-9451; FDC with GS-9669

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients.
Fixed Dose GS-7977/GS-5885; FDC with GS-9451; FDC with GS-9669

Chronic Hepatitis B e Antigen Positive, or Chronic Hepatitis B e Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Withdrawal of Therapy After Long-Term Oral Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B.

Hepatitis C, or HIV Infections Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications.

Chronic Hepatitis C Virus, or Non Alcoholic Fatty Liver Disease Clinical Trial using normocaloric low cholesterol diet

University of Roma La Sapienza - Recruiting 40 years to 70 years.
- Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano.
normocaloric low cholesterol diet

Chronic Hepatitis C Clinical Trial using TMC647055; TMC435; Ritonavir; Ribavirin; Pegylated interferon alpha-2a (PegIFN); GSK2336805

Janssen R&D Ireland - Recruiting 18 years to 70 years.
- A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients.
TMC647055; TMC435; Ritonavir; Ribavirin; Pegylated interferon alpha-2a (PegIFN); GSK2336805

Hepatitis C, Chronic Clinical Trial using Pegylated interferon alfa 2b; Ribavirin

Kirby Institute - Recruiting 18 years or older.
- A Phase IV, Open-label, Multicentre, International Trial of Response Guided Treatment With Directly Observed Pegylated Interferon Alfa 2b and Self Administered Ribavirin for Patients With Chronic HCV Genotype 2 or 3 and Injection Drug Use.
Pegylated interferon alfa 2b; Ribavirin

Hepatitis, or Hepatitis C Clinical Trial using Algeron; Pegasys

Biocad - Recruiting 18 years to 70 years.
- An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C.
Algeron; Pegasys

Chronic Hepatitis C Clinical Trial using Sofosbuvir; RBV; PEG

Gilead Sciences - Recruiting 18 years or older.
- An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies.
Sofosbuvir; RBV; PEG

Hepatitis C, Chronic Clinical Trial using Simprenavir; Daclatasvir; Ribavarin

Janssen R&D Ireland - Recruiting 18 years or older.
- Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation.
Simprenavir; Daclatasvir; Ribavarin

Chronic Hepatitis B Clinical Trial using peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly; Nucleos(t)ide analogue therapy

National University Health System, Singapore - Recruiting 21 years to 65 years.
- SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL).
peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly; Nucleos(t)ide analogue therapy

Hepatitis C Clinical Trial using boceprevir; PegIFN-2b; RBV

Merck Sharp & Dohme Corp. - Recruiting 18 years to 75 years.
- A Multi-centre Single-arm Study to Evaluate the Efficacy and Safety of BOCEPREVIR 44 Weeks in Addition to Standard of Care (SOC) in Previously Treatment Failure (Relapser, Non-responders, Both Partial and Null) Patients With Chronic Hepatitis C Genotype 1 (G1) and Cirrhosis (F4 Metavir). (MK-3034-105-00).
boceprevir; PegIFN-2b; RBV

Chronic Hepatitis C(CHC) Clinical Trial using MP-424; RBV; IFN beta

Mitsubishi Tanabe Pharma Corporation - Recruiting 20 years to 70 years.
- A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Na‹ve or Have Received Interferon Based Therapy.
MP-424; RBV; IFN beta

HBV, or Chronic HBV Infections Clinical Trial using Tenofovir alafenamide; Tenofovir DF; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B.
Tenofovir alafenamide; Tenofovir DF; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF

HBV, or Chronic HBV Infections Clinical Trial using Tenofovir alafenamide; Tenofovir disoproxil fumarate; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B.
Tenofovir alafenamide; Tenofovir disoproxil fumarate; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF

Hepatitis C Virus Clinical Trial using ABT-450/r/ABT-267 plus Ribavirin

AbbVie - Recruiting 18 years to 75 years.
- An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Na‹ve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II).
ABT-450/r/ABT-267 plus Ribavirin

Human Immunodeficiency Virus (HIV), or Hepatitis C, Chronic Clinical Trial

George Washington University - Recruiting 18 years or older.
- The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System..

Hepatitis C, Chronic Clinical Trial using Telaprevir and Sofosbuvir

University of Florida - Recruiting 18 years or older.
- Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1.
Telaprevir and Sofosbuvir

Hepatitis C Clinical Trial using Sofosbuvir; RBV; PEG

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection..
Sofosbuvir; RBV; PEG

Early Chronic Hepatitis C Clinical Trial using TPV/PEG-IFN/RBV

Kirby Institute - Recruiting 18 years to 60 years.
- DAA Based Therapy for Recently Acquired Hepatitis C.
TPV/PEG-IFN/RBV

Chronic Hepatitis C Infection Clinical Trial using Pegylated Interferon Lambda-1a; Daclatasvir (DCV); Ribasphere (RBV)

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment na‹ve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With HIV.
Pegylated Interferon Lambda-1a; Daclatasvir (DCV); Ribasphere (RBV)

Liver Fibrosis Clinical Trial

Yonsei University - Recruiting 19 years to 80 years.
- .

Chronic HIV Infection, or HCV Coinfection Clinical Trial using Fosamprenavir

Fundacion SEIMC-GESIDA - Recruiting 18 years or older.
- Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir.
Fosamprenavir

HBeAg-Positive Chronic Hepatitis B Clinical Trial using Baracle Tab.r; Baraclude Tab.r

Dong-A Pharmaceutical Co., Ltd. - Recruiting 18 years to 65 years.
- A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.r and Baraclude Tab.r for HBeAG Chronic Hepatitis B.
Baracle Tab.r; Baraclude Tab.r

Hepatitis C Clinical Trial using Pegylated Interferon Lambda; Ribasphere; Daclatasvir

Bristol-Myers Squibb - Recruiting 18 years to 70 years.
- A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment na‹ve Subjects.
Pegylated Interferon Lambda; Ribasphere; Daclatasvir

Chronic Hepatitis C Clinical Trial

Beijing 302 Hospital - Recruiting 1 year to 18 years.
- Pharmacogenomics Study on IL28B Genetic Variants for Prediction of Drug Response in Chinese Children With HCV Infection..

Chronic Hepatitis C Clinical Trial using Pegylated interferon alfa-2a + ribavirin

National Taiwan University Hospital - Recruiting 18 years or older.
- Peginterferon Alfa-2a Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Stratified by Rapid Virologic Response.
Pegylated interferon alfa-2a + ribavirin

Chronic Hepatitis C, Chronic Hepatitis B, Biopsy, or Hemodialysis Clinical Trial using Percutaneous liver biopsy

National Taiwan University Hospital - Recruiting N/A or older.
- Safety Profiles of Percutaneous Liver Biopsy in Hemodialysis Patients With Chronic Hepatitis C Pre-treated With 1-Deamino-8- D-Arginine Vasopressin.
Percutaneous liver biopsy

Hepatitis B, Chronic Clinical Trial using Entecavir and peginterferon alfa-2a; Placebo and peginterferon

National Taiwan University Hospital - Recruiting 18 years or older.
- Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B.
Entecavir and peginterferon alfa-2a; Placebo and peginterferon

Chronic Hepatitis C Clinical Trial using ChronVac-C + SOC; SOC

ChronTech Pharma AB - Recruiting 18 years to 65 years.
- A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Na‹ve Subjects.
ChronVac-C + SOC; SOC

Chronic Hepatitis C Clinical Trial using Quercetin

University of California, Los Angeles - Recruiting 18 years to 65 years.
- A Phase 1 Study of Quercetin in Patients With Hepatitis C.
Quercetin

Chronic Hepatitis B Clinical Trial using Tenofovir; Telbivudine; Tenofovir plus Telbivudine

Institute of Liver and Biliary Sciences, India - Recruiting 18 years to 65 years.
- An Exploratory, Randomized, Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug Alone in HBeAg Negative Chronic Hepatitis B Patients.
Tenofovir; Telbivudine; Tenofovir plus Telbivudine

Hepatitis C, Chronic, or HIV Infection Clinical Trial using Adherence questionnaire

Fundacion IMIM - Recruiting 18 years or older.
- Development and Validation of a Questionnaire Measuring Treatment Adherence in Patients With Hepatitis C.
Adherence questionnaire

Chronic HCV Infection, or Nonalcoholic Steatohepatitis Clinical Trial using pegylated interferon; Ribavarin

Charles University, Czech Republic - Recruiting 18 years to 60 years.
- Role of Heme Oxygenase in the Pathogenesis od Hepatocellular Injury in Chronic HCV Infection.
pegylated interferon; Ribavarin

Hepatitis C, Hepatitis B, Autoimmune Hepatitis, Liver Cirrhosis, Clinical Trial

University Health Network, Toronto - Recruiting 18 years to 85 years.
- Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease.

Hepatitis C, or Hepatitis B Clinical Trial using Pegasys; Copegus.

University Health Network, Toronto - Recruiting 18 years to 85 years.
- Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Anti-Viral Therapy.
Pegasys; Copegus.